47.41 USD
-0.34 (-0.71%)
48.33 USD
+0.92 (+1.94%)
Overall VCYT gets a fundamental rating of 6 out of 10. We evaluated VCYT against 534 industry peers in the Biotechnology industry. While VCYT has a great health rating, its profitability is only average at the moment. VCYT is growing strongly while it is still valued neutral. This is a good combination! This makes VCYT very considerable for growth investing!
1. Profitability
1.1 Basic Checks
VCYT had positive earnings in the past year.
VCYT had a positive operating cash flow in the past year.
In the past 5 years VCYT reported 4 times negative net income.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
VCYT has a Return On Assets of 2.22%. This is amongst the best in the industry. VCYT outperforms 89.89% of its industry peers.
The Return On Equity of VCYT (2.41%) is better than 91.01% of its industry peers.
VCYT's Return On Invested Capital of 2.93% is amongst the best of the industry. VCYT outperforms 90.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT has a Profit Margin of 6.12%. This is amongst the best in the industry. VCYT outperforms 90.82% of its industry peers.
VCYT has a better Operating Margin (9.70%) than 91.57% of its industry peers.
VCYT has a Gross Margin of 68.53%. This is amongst the best in the industry. VCYT outperforms 80.71% of its industry peers.
VCYT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VCYT is destroying value.
The number of shares outstanding for VCYT has been increased compared to 1 year ago.
The number of shares outstanding for VCYT has been increased compared to 5 years ago.
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VCYT has an Altman-Z score of 20.80. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
VCYT's Altman-Z score of 20.80 is amongst the best of the industry. VCYT outperforms 90.07% of its industry peers.
There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.8 |
ROIC/WACC0.34
WACC8.7%
2.3 Liquidity
VCYT has a Current Ratio of 6.23. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.23, VCYT is in the better half of the industry, outperforming 65.73% of the companies in the same industry.
A Quick Ratio of 5.94 indicates that VCYT has no problem at all paying its short term obligations.
VCYT has a Quick ratio of 5.94. This is in the better half of the industry: VCYT outperforms 63.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 353.33% over the past year.
Looking at the last year, VCYT shows a quite strong growth in Revenue. The Revenue has grown by 16.41% in the last year.
Measured over the past years, VCYT shows a very strong growth in Revenue. The Revenue has been growing by 29.93% on average per year.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
The Earnings Per Share is expected to grow by 52.24% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.54% on average over the next years. This is quite good.
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y52.24%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y11.54%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 124.76 indicates a quite expensive valuation of VCYT.
Based on the Price/Earnings ratio, VCYT is valued cheaply inside the industry as 89.14% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of VCYT to the average of the S&P500 Index (26.41), we can say VCYT is valued expensively.
A Price/Forward Earnings ratio of 56.11 indicates a quite expensive valuation of VCYT.
VCYT's Price/Forward Earnings ratio is rather cheap when compared to the industry. VCYT is cheaper than 89.51% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, VCYT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.76 | ||
| Fwd PE | 56.11 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VCYT is valued cheaper than 91.01% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 92.70% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.16 | ||
| EV/EBITDA | 47.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCYT does not grow enough to justify the current Price/Earnings ratio.
VCYT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 57.77% in the coming years.
PEG (NY)3.76
PEG (5Y)N/A
EPS Next 2Y67.82%
EPS Next 3Y57.77%
5. Dividend
5.1 Amount
VCYT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
47.41
-0.34 (-0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.55%
Inst Owner Change3.31%
Ins Owners0.56%
Ins Owner Change-1.77%
Market Cap3.75B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts83.33
Price Target48.22 (1.71%)
Short Float %6.93%
Short Ratio5.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)14.68%
PT rev (3m)14.68%
EPS NQ rev (1m)9.91%
EPS NQ rev (3m)17.87%
EPS NY rev (1m)5.86%
EPS NY rev (3m)6.58%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)0.46%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.76 | ||
| Fwd PE | 56.11 | ||
| P/S | 7.57 | ||
| P/FCF | 38.16 | ||
| P/OCF | 34.62 | ||
| P/B | 2.98 | ||
| P/tB | 9.42 | ||
| EV/EBITDA | 47.32 |
EPS(TTM)0.38
EY0.8%
EPS(NY)0.84
Fwd EY1.78%
FCF(TTM)1.24
FCFY2.62%
OCF(TTM)1.37
OCFY2.89%
SpS6.26
BVpS15.91
TBVpS5.04
PEG (NY)3.76
PEG (5Y)N/A
Graham Number11.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | 20.8 |
F-Score8
WACC8.7%
ROIC/WACC0.34
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y52.24%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y11.54%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.46%
EBIT Next 3Y68.01%
EBIT Next 5Y47.08%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 6 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 5 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 8 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 33.17% in the next year.